[{"address1": "200 Arsenal Yards Boulevard", "address2": "Suite 230", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 184, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 75000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1075600, "exercisedValue": 457971, "unexercisedValue": 20455824}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 671200, "exercisedValue": 249766, "unexercisedValue": 5641756}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 614498, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 65, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 640345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723600, "exercisedValue": 0, "unexercisedValue": 4995031}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 36.63, "open": 36.99, "dayLow": 36.36, "dayHigh": 37.79, "regularMarketPreviousClose": 36.63, "regularMarketOpen": 36.99, "regularMarketDayLow": 36.36, "regularMarketDayHigh": 37.79, "beta": 2.188, "forwardPE": -11.43534, "volume": 457904, "regularMarketVolume": 457904, "averageVolume": 488461, "averageVolume10days": 465050, "averageDailyVolume10Day": 465050, "bid": 26.95, "ask": 46.73, "bidSize": 200, "askSize": 200, "marketCap": 2388544256, "fiftyTwoWeekLow": 29.24, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 27.27801, "fiftyDayAverage": 41.0561, "twoHundredDayAverage": 41.70905, "currency": "USD", "enterpriseValue": 1926804352, "profitMargins": -1.91261, "floatShares": 43349341, "sharesOutstanding": 64765300, "sharesShort": 7690384, "sharesShortPriorMonth": 8772474, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1187, "heldPercentInsiders": 0.013049999, "heldPercentInstitutions": 1.11323, "shortRatio": 14.94, "shortPercentOfFloat": 0.13260001, "impliedSharesOutstanding": 64765300, "bookValue": 13.791, "priceToBook": 2.674208, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -167474000, "trailingEps": -2.34, "forwardEps": -3.11, "enterpriseToRevenue": 22.005, "enterpriseToEbitda": -10.115, "52WeekChange": -0.03681302, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "KYMR", "underlyingSymbol": "KYMR", "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "firstTradeDateEpochUtc": 1598016600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fe087242-38df-325c-aac8-26165faa63ce", "messageBoardId": "finmb_542085131", "gmtOffSetMilliseconds": -18000000, "currentPrice": 36.88, "targetHighPrice": 97.0, "targetLowPrice": 41.0, "targetMeanPrice": 58.84211, "targetMedianPrice": 57.0, "recommendationMean": 1.55, "recommendationKey": "buy", "numberOfAnalystOpinions": 19, "totalCash": 549969984, "totalCashPerShare": 8.492, "ebitda": -190490000, "totalDebt": 88231000, "quickRatio": 8.286, "currentRatio": 8.548, "totalRevenue": 87563000, "debtToEquity": 9.881, "revenuePerShare": 1.258, "returnOnAssets": -0.15378, "returnOnEquity": -0.25996, "grossProfits": -133838000, "freeCashflow": -94098128, "operatingCashflow": -124672000, "revenueGrowth": -0.209, "grossMargins": -1.52848, "ebitdaMargins": -2.17546, "operatingMargins": -19.279339, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]